Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders

Basit Öğe Kaydı
dc.contributor.authorGadgeel, S. M.
dc.contributor.authorSoria, J. C.
dc.contributor.authorFelip, E.
dc.contributor.authorCobo, M.
dc.contributor.authorLu, S.
dc.contributor.authorSyrigos, K.
dc.contributor.authorLee, K. H.
dc.contributor.authorGoker, E.
dc.contributor.authorGeorgoulias, V.
dc.contributor.authorLi, W.
dc.contributor.authorGuclu, S.
dc.contributor.authorIsla, D.
dc.contributor.authorArdizzoni, A.
dc.contributor.authorDupuis, N.
dc.contributor.authorGibson, N.
dc.contributor.authorKraemer, N.
dc.contributor.authorBuehnemann, C.
dc.contributor.authorSolca, F.
dc.contributor.authorEhrnrooth, E.
dc.contributor.authorGoss, G.
dc.date.accessioned2019-10-27T11:11:10Z
dc.date.available2019-10-27T11:11:10Z
dc.date.issued2017
dc.departmentEge Üniversitesien_US
dc.descriptionEuropean-Cancer-Organisation (ECCO) European Cancer Congress -- JAN 27-30, 2017 -- Amsterdam, NETHERLANDSen_US
dc.description.sponsorshipEuropean Canc Orgen_US
dc.identifier.endpageS185en_US
dc.identifier.issn0959-8049
dc.identifier.issn1879-0852
dc.identifier.startpageS185en_US
dc.identifier.urihttps://hdl.handle.net/11454/32468
dc.identifier.volume72en_US
dc.identifier.wosWOS:000417650200582en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofEuropean Journal of Canceren_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleSecond-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term respondersen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu